Article Text

Download PDFPDF

Original article
Nuclear orphan receptor NR2F6 as a safeguard against experimental murine colitis
  1. Victoria Klepsch1,
  2. Romana R Gerner2,
  3. Sebastian Klepsch1,
  4. William J Olson1,
  5. Herbert Tilg2,
  6. Alexander R Moschen2,
  7. Gottfried Baier1,
  8. Natascha Hermann-Kleiter1
  1. 1 Translational Cell Genetics, Department for Pharmacology and Genetics, Medical University of Innsbruck, Innsbruck, Tirol, Austria
  2. 2 Department of Internal Medicine I, Gastroenterology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, Tirol, Austria
  1. Correspondence to Prof. Dr. Gottfried Baier; gottfried.baier{at}i-med.ac.at and Assoc. Prof. Dr. Natascha Hermann-Kleiter; natascha.kleiter{at}i-med.ac.at

Abstract

Objective Nuclear receptors are known to regulate both immune and barrier functions in the GI tract. The nuclear orphan receptor NR2F6 has been shown to suppress the expression of proinflammatory cytokines in T lymphocytes. NR2F6 gene expression is reduced in patients with IBS or UC, but its functional role and tissue dependency in healthy and inflamed gut have not yet been investigated.

Design Intestinal inflammation was induced in wild-type, Nr2f6-deficient, Rag1-deficient or bone marrow-reconstituted mice by administration of chemical (dextran sodium sulfate (DSS)) and immunogenic (T cell transfer) triggers. Disease phenotypes were investigated by survival, body weight, colon length and analysis of immune cell infiltrates. Additionally, histology, intestinal permeability, tight junction proteins, bacterial fluorescence in situ hybridisation, apoptosis, cell proliferation and mucus production were investigated.

Results Nr2f6-deficient mice were highly susceptible to DSS-induced colitis characterised by enhanced weight loss, increased colonic tissue destruction and immune cell infiltration together with enhanced intestinal permeability and reduced Muc2 expression. T cell transfer colitis and bone marrow reconstitution experiments demonstrated that disease susceptibility was not dependent on the expression of Nr2f6 in the immune compartment but on the protective role of NR2F6 in the intestinal epithelium. Mechanistically, we show that NR2F6 binds to a consensus sequence at −2 kb of the Muc2 promoter and transactivates Muc2 expression. Loss of NR2F6 alters intestinal permeability and results in spontaneous late-onset colitis in Nr2f6-deficient mice.

Conclusion We have for the first time identified a fundamental and non-redundant role of NR2F6 in protecting gut barrier homeostasis.

  • nuclear receptor
  • colitis
  • inflammation
  • intestinal epithelial barrier

This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • GB and NH-K contributed equally.

  • Contributors The study was designed by VK, AR-M, GB and N-HK. VK did experiments together with RG-R; SK, WJ-O and N-HK. VK, RR-G, AR-M and N-HK analysed the data. VK, AR-M, HT, GB and N-HK discussed and interpreted findings. VK, GB, and N-HK directed the work and wrote the manuscript. All of the authors have seen and approved the final version of the manuscript.

  • Funding This work was supported by grants from the FWF Austrian Science Fund (W1101-B18, P28694-B30 (granted to N-HK), P25044-B21Tyrolean Science Funds 0404/1480, the Austrian Christian Doppler Society (CDL I-CARE granted to GB) as well as the Krebshilfe Tirolfund (granted to VK).

  • Competing interests None declared.

  • Ethics approval All animal experiments were performed in accordance to the Austrian “Tierversuchsgesetz” (BMWF-66.011/0061-II/3b/2013,BMWF-66.011/0128-WF/V/3b/2016, BMWF-66.011/0186-WF/V/3b/2016) and were approved by the Bundesministerium für Wissenschaft und Forschung (bm:wf).

  • Provenance and peer review Not commissioned; externally peer reviewed.